No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PHR240719C17500
- 2.50
- 0.000.00%
15min DelayTrading May 31 10:10 ET
0.00High0.00Low
0.00Open2.50Pre Close0 Volume1 Open Interest17.50Strike Price0.00Turnover70.73%IV-0.89%PremiumJul 19, 2024Expiry Date2.68Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8879Delta0.0749Gamma7.02Leverage Ratio-0.0230Theta0.0048Rho6.23Eff Leverage0.0069Vega
Intraday
- 5D
- Daily
News
Possible Bearish Signals With Phreesia Insiders Disposing Stock
Over the past year, many Phreesia, Inc. (NYSE:PHR) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether i
Phreesia Is Maintained at Buy by Truist Securities
Phreesia Is Maintained at Buy by Truist Securities
A Glimpse Into The Expert Outlook On Phreesia Through 6 Analysts
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months.The table below provides a snapshot of their recent
Express News | Truist Securities Maintains Buy on Phreesia, Maintains $29 Price Target
Phreesia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 40.4% Truist Securities $29 → $29 Maintains Buy 06/03/2024 40.4% Truist Securities $35 → $29 Ma
Truist Financial Maintains Phreesia(PHR.US) With Buy Rating
Truist Financial analyst Jailendra Singh maintains $Phreesia(PHR.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 29.9% and a total average return of -16.2% over th
Comments
Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.
Phreesia, Inc.'s (NYSE:PHR) P/S Is Still On The Mark Following 43% Share Price Bounce
Gainers:
• $Okta(OKTA.US$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
• $Okta(OKTA.US$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
25
2
Upgrades
• $CDW Corp(CDW.US$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc.(CXW.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines(DAL.US$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller(FUL.US$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries(HII.US$ : Cowen U...
• $CDW Corp(CDW.US$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc.(CXW.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines(DAL.US$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller(FUL.US$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries(HII.US$ : Cowen U...
19
Gainers:
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
14
Read more